Investments & digital assets › F8949.A.X211
F8949.A.X211 · federal · F8949 line A.X211
Delmar Pharma (acquired 2024-06-05, sold 2025-03-20; proceeds 1,745.56, basis 1,651.87)
93.69
engine v3
not yet verified
How this number was built
R-8949-LOT One line per sale: proceeds minus basis plus adjustment. Broker basis is used as reported unless a supplemental statement for the same lot is matched.
Sources (6) — where the inputs came from
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_desc · “Lot X211 description”
read as “Delmar Pharma” → Delmar Pharma
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_acq · “Lot X211 date acquired”
read as “06/05/2024” → 2024-06-05
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_sold · “Lot X211 date sold”
read as “03/20/2025” → 2025-03-20
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_proceeds · “Lot X211 proceeds”
read as “1,745.56” → 1,745.56
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_basis · “Lot X211 cost basis”
read as “1,651.87” → 1,651.87
99%
Brightpath Advisors 2025 Form 1099-B (direct-indexing account)
D74 · page 7 · field X211_wash · “Lot X211 wash sale loss disallowed”
read as “0.00” → 0
99%
Flows into
History — nothing is overwritten
v1 · 2026-03-04: 93.69v2 · 2026-03-19: 93.69v3 · 2026-06-23: 93.69
Adjust this number
Evidence & discussion
Record how you verified it